Skip to main content

What’s New in Rezum: a Transurethral Water Vapour Therapy for BPH

Abstract

Purpose of Review

Rezum is a new minimally invasive treatment for benign prostate enlargement using thermal transurethral water vapour therapy. We review the evidence with advantages and disadvantages of this technique.

Recent Findings

There are five studies reported including a randomised control trial looking at the outcomes of Rezum. The outcomes show an IPSS reduction by 45–60%, QoL improvement with a score reduction of 37–59%, the Qmax improvement by 44–72% and the PVR reduction by 20–38%.

Summary

Convective water vapour therapy using the Rezum system has been shown to have successful outcomes in the treatment of LUTS resulting from BPH. The reported complications are infrequent and often minor, and it seems to be relatively cost-effective.

This is a preview of subscription content, access via your institution.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.

    Bin LK. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. Elsevier Ltd. 2017;4(3):148–51.

    Article  Google Scholar 

  2. 2.

    Abrams P, Cardozo L, Fall M, Griffiths D, Rosear P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn [Internet. 2002;178:167–78.

    Article  Google Scholar 

  3. 3.

    Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int. 2015;115:508–19.

    Article  Google Scholar 

  4. 4.

    Barry MJ. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology. 2001;58(01):25–32.

    CAS  Article  Google Scholar 

  5. 5.

    EAU Guidelines. Edn. Presented at the EAU Annual Congress Copenhagen. Arnhem: EAU Guidelines Office; 2018. https://uroweb.org/guidelines/compilations-of-all-guidelines. Accessed 3 March 2019.

  6. 6.

    Van AB, Barkin J, Elterman DS, Czerniak B, Dinney C, McConkey D, et al. Hyperplasia : a review. Curr Opin Oncol. 2014;23:863–910.

    Google Scholar 

  7. 7.

    Foster HE, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol. 2018;

  8. 8.

    Jones P, Rajkumar GN, Rai BP, Aboumarzouk OM, Cleaveland P, Srirangam SJ, et al. Medium-term outcomes of Urolift (minimum 12 months follow-up): evidence from a systematic review. Urology. Elsevier Inc. 2016;97:20–4.

    Article  Google Scholar 

  9. 9.

    Jones P, Rai BP, Nair R, Somani BK. Current status of prostate artery embolization for lower urinary tract symptoms: review of world literature. Urology. 2015:676–81.

    Article  Google Scholar 

  10. 10.

    •• McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology [internet]. Elsevier Inc.; 2019;126:171–179. This paper outlines data collected in the only double blinded randomised control trial using Rezum. As of 2019 data are avialble for four years post implementation of the therapy. The study also features the largest number of participants.

    Article  Google Scholar 

  11. 11.

    National Institute for Health and Care Excellence (NICE). Medtech innovation briefing (MIB158). Rezum for treating benign prostatic hyperplasia. London: NICE; 2018.

  12. 12.

    • Mynderse LA, Hanson D, Robb RA, Pacik D, Vit V, Varga G et al. Rezu¯m system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology. Elsevier Inc.; 2015;86(1):122–7. This paper provided objective data on the efficacy of Rezum and its viability for bringing about reduction in prostatic volume.

    Article  Google Scholar 

  13. 13.

    Somani BK, Westwood J, Rai BP, Jones P, Geraghty R. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. Ther Adv Urol. 2018;10:327–33.

    Article  Google Scholar 

  14. 14.

    Gittelman MC, Gange SN, Patel K, Roehrborn CG, Beahrs JR, Levin RM, et al. Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol Elsevier Ltd. 2016;197(6):1507–16.

    PubMed  Google Scholar 

  15. 15.

    Dixon C, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Efficacy and safety of Rezūm system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. Elsevier Inc. 2015;86(5):1042–7.

    Article  Google Scholar 

  16. 16.

    Dixon CM, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol. 2016;8:207–16.

    PubMed  PubMed Central  Google Scholar 

  17. 17.

    Shore ND, McVary KT, Roehrborn CG, Kaminetsky J, Dixon CM, Cantrill CH, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol Elsevier Ltd. 2015;195(5):1529–38.

    PubMed  Google Scholar 

  18. 18.

    Roehrborn CG, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol. 2017;197:1507–16.

    Article  Google Scholar 

  19. 19.

    Darson MF, Alexander EE, Schiffman ZJ, Lewitton M, Light RA, Sutton MA, et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Rep Urol. 2017;9:159–68.

    PubMed  PubMed Central  Google Scholar 

  20. 20.

    Mollengarden D, Goldberg K, Wong D, Roehrborn C. Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience. Prostate Cancer Prostatic Dis Springer US. 2018;21:379–85.

    Article  Google Scholar 

  21. 21.

    Gupta N, Rogers T, Holland B, Helo S, Dynda D, McVary KT. Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial. J Urol [Internet] Elsevier Ltd. 2018;200(2):405–13.

    CAS  Article  Google Scholar 

  22. 22.

    McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study. J Sex Med [Internet] Elsevier. 2016;13(6):924–33.

    Article  Google Scholar 

  23. 23.

    McVary KT, Rogers T, Mahon J, Gupta NK. Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia? J Sex Med. 2018;15:1728–38.

    Article  Google Scholar 

  24. 24.

    • Ulchaker J, Martinson M. Analyzing the Cost-Effectiveness of Six Therapies for Treating Lower Urinary Tract Symptoms Due To Benign Prostatic Hyperplasia. J Urol. 2018;199:29–43 In-depth analysis of the costs associated with new minimally invasive prosate therapies. Highlights potential for implementation within various health services.

    Article  Google Scholar 

  25. 25.

    Otto B, et al. Incidental prostate cancer in transurethral resection of the prostate specimens in the modern era. Advances Urol. 2014;2014:627290. https://doi.org/10.1155/2014/627290.

    Article  Google Scholar 

  26. 26.

    Abedi AR, Fallah-Karkan M, Allameh F, Ranjbar A, Shadmehr A. Incidental prostate cancer: a 10-year review of a tertiary center, Tehran, Iran. Res Rep Urol. 2018;10:1–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. 27.

    McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled Rezūm system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology Elsevier Inc. 2018;111:1–9.

    Article  Google Scholar 

Download references

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jennifer Westwood.

Ethics declarations

Conflict of Interest

Zachary Green and Jennifer Westwood each declare no potential conflicts of interest.

Bhaskar K. Somani is a section editor for Current Urology Reports.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Benign Prostatic Hyperplasia

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Green, Z., Westwood, J. & Somani, B.K. What’s New in Rezum: a Transurethral Water Vapour Therapy for BPH. Curr Urol Rep 20, 39 (2019). https://doi.org/10.1007/s11934-019-0903-7

Download citation

Keywords

  • Rezum
  • Water vapour therapy
  • BPH
  • LUTS
  • Minimally invasive therapy
  • TURP